Opinions
Matt Kacur
Teva Pharmaceutical
TEVA-N
COMMENT
Jan 06, 2017
$35.100
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology
pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology
pharmaceutical
DON'T BUY
His data is telling him that this is a tremendous company. ROC for years and years has been 12% or higher. In the last few years, it has been in the 20% range. However, it has not done so great in the last year or so. He would say that this is an opportunity. There are probably some issues in the pipeline that you would want to work through and understand a little better, and that is not his forte.